Recruiting OBSERVATIONAL NCT07444801
Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact (AD Genital)
Sponsor: LEO Pharma
Interventions
tralokinumab
Updated 1 time since 2026 Last updated: Feb 24, 2026 Started: Oct 20, 2025 Primary completion: Oct 31, 2027 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A observational or N/A phase clinical study on Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region, this trial is actively recruiting participants. The trial is conducted by LEO Pharma and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- LEO Pharma
- University Hospital Schleswig-Holstein
Data source: University Hospital Schleswig-Holstein
For direct contact, visit the study record on ClinicalTrials.gov .